Skip to main content
. 2023 Jul 25;12(15):4882. doi: 10.3390/jcm12154882

Table 1.

Summary of in-human studies investigating HER2-targeted radiotracers.

Imaging Modality n Patients Radiotracer Primary Objective Year First Author PMID Citation
PET/CT 16 89Zr-Trastuzumab Treatment response 2014 Gaykema 25085789 [15]
11 Detection of HER2+ metastases 2017 Ulaner 28872549 [16]
14 Feasibility study 2010 Dijkers 20357763 [17]
9 Detection of HER2+ metastases 2016 Ulaner 27151988 [18]
20 HER2 status determination 2018 Bensch 30058029 [19]
34 HER2 status determination 2018 Dehdashti 29442264 [20]
12 Feasibility study 2016 Laforest 27146421 [21]
10 HER2 status determination 2019 Jauw 31147401 [22]
PET/CT 22 89Zr-Atezolizumab Feasibility study 2018 Bensch 30478423 [23]
PET/CT 6 89Zr-Pertuzumab Feasibility study 2017 Ulaner 29146695 [24]
24 89Zr-Pertuzumab Detection of HER2+ metastases 2020 Ulaner 32515679 [25]
PET/CT 1 89Zr-Fab * Feasibility study 2020 Richter, Knorr 32377263 [26]
PET/CT 1 68Ga-ZHER2 Detection of HER2+ metastases 2020 Zhou 31833926 [27]
PET/CT 20 68Ga-nanobody Feasibility study 2015 Keyaerts 26449837 [28]
PET/CT 16 68Ga-affibody Feasibility study 2016 Sorensen 26877784 [29]
24 HER2 status determination 2022 Miao 35712499 [30]
8 Feasibility study 2016 Sandstrom 26912439 [31]
PET/CT 6 64Cu-Trastuzumab Feasibility study 2013 Tamura 24029656 [32]
38 HER2 status determination 2017 Sasada 28505219 [33]
8 Feasibility study 2016 Carrasquillo 27171605 [34]
5 Detection of HER2+ metastases 2015 Kurihara 25853014 [35]
8 HER2 status determination 2014 Mortimer 24337604 [36]
11 HER2 status determination 2018 Mortimer 28637802 [37]
7 Feasibility study 2021 Lee 33475899 [38]
1 HER2 status determination 2022 Lee 35133094 [39]
1 HER2 status determination 2017 Sasada 28770275 [40]
PET/CT 7 64Cu-SAR † Feasibility study 2022 Wong 35890071 [41]
PET/CT 11 177Lu-Trastuzumab Feasibility study 2021 Nautiyal 34406146 [42]
PET/CT 3 111In/68Ga-affibody HER2 status determination 2010 Baum 20484419 [43]
SPECT/CT 23 Feasibility study 2017 Sandberg 28261749 [44]
SPECT/CT 7 111In-affibody Feasibility study 2014 Sörensen 24665085 [45]

* Fab indicates antibody fragment. † SAR indicates a Sarcophagine ligand.